Irinotecan Hcl-Trihydraat Fresenius Kabi

Irinotecan, the active ingredient in Irinotecan Hcl-Trihydraat Fresenius Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats metastatic and advanced colorectal cancer, including adjuvant therapy, in adult patients.

GNH USA supplies Irinotecan Hcl-Trihydraat Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

Metastatic colorectal cancer: improves overall survival when combined with standard chemotherapy regimens. Advanced colorectal cancer: provides disease control for patients with unresectable disease. Adjuvant therapy for colorectal cancer: reduces the risk of recurrence after surgical resection.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: may be managed with antiemetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss during treatment. - Fatigue: generalized tiredness affecting daily activities. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring immediate medical attention. - Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance. - Hepatotoxicity: liver enzyme elevations indicating potential liver injury.

Before initiating therapy, clinicians should assess patient suitability and monitor for known risks.

Baseline blood counts: obtain complete blood count to detect pre‑existing neutropenia. Liver function: evaluate hepatic enzymes as impaired function can increase toxicity. Renal function: adjust monitoring in patients with reduced clearance. Pregnancy and lactation: avoid use due to unknown safety profile; discuss alternatives. Drug interactions: review concomitant medications for potential CYP3A4 modulators. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Irinotecan interacts with several agents that can modify its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce SN‑38 exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase SN‑38 levels and risk of severe toxicity. - UGT1A1 inhibitors (e.g., atazanavir): may impair SN‑38 glucuronidation, raising toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to platelet suppression. - Other myelosuppressive agents: additive bone‑marrow depression. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - Granulocyte colony‑stimulating factors: may reduce neutropenia duration. - Herbal supplements (e.g., St. John’s wort): potential CYP3A4 induction.